Glaucoma and Dry Eye

Dry eye disease and glaucoma often occur together, especially because some glaucoma eye drops can affect the tear film and make symptoms like burning, irritation, watering, or fluctuating vision worse. Early diagnosis and treatment of both conditions can improve comfort and help protect long-term vision.

Glaucoma and dry eye disease occur together more often than chance alone explains. If your eyes burn, sting, or feel gritty while you are on glaucoma drops, you are not imagining it. This combination is common, clinically important, and often undertreated.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


How Common Is Glaucoma and Dry Eye Overlap?

Studies consistently show that 40 to 60 percent of glaucoma patients meet diagnostic criteria for dry eye disease. The reverse is also true: people with moderate to severe dry eye carry a higher risk of developing glaucoma-related damage. These are not coincidental companions. They share biological mechanisms, and each condition can quietly worsen the other.


Why Does Dry Eye Develop in Glaucoma Patients?

The preservative problem

Most glaucoma eye drops contain benzalkonium chloride (BAK) as a preservative. BAK is effective at keeping the bottle sterile, but it is toxic to the cells of the ocular surface. It disrupts the tear film, damages goblet cells (the cells that produce the mucin layer of your tears), and triggers chronic inflammation.

Patients who use two or three glaucoma drops daily — each containing BAK — are exposing their eyes to this preservative four, six, or more times every day. Over months and years, the cumulative damage is significant. The conjunctiva becomes inflamed, the cornea loses its smooth optical surface, and the eyes feel perpetually uncomfortable.

This is not a rare side effect. It is an expected biological consequence of long-term BAK exposure, and it is one of the most underrecognised sources of glaucoma-related suffering.

Pre-existing risk

Dry eye disease is more common in the same demographic groups that develop glaucoma: older adults, women after menopause, and people with autoimmune conditions. Many patients arrive at a glaucoma diagnosis already carrying a degree of ocular surface disease. Adding BAK-containing drops to a compromised surface accelerates the damage.

Reduced blink rate

Glaucoma patients and patients with dry eye often share a common modern risk factor: prolonged screen use. Reduced blink rate during screen time is one of the fastest-growing contributors to evaporative dry eye, and it worsens the tolerance to topical medications.


Why Does This Overlap Matter Clinically?

Medication adherence

Dry eye makes glaucoma drops uncomfortable. Burning, stinging, and a sense of grittiness after instillation are among the most common reasons patients quietly reduce their drop frequency or stop altogether. This is rational behaviour in response to pain — but the result is uncontrolled intraocular pressure and silent glaucoma progression.

Treating dry eye is not a cosmetic afterthought. It is a strategy for protecting adherence, which protects the optic nerve.

Diagnostic accuracy

Dry eye causes variable intraocular pressure readings. Epithelial irregularity from a damaged ocular surface can affect tonometry (pressure measurement) and cause artificially high or variable readings. This creates noise in the data your glaucoma specialist depends on.

Similarly, a poor ocular surface causes artefacts in OCT scans and visual field tests. Blurring from unstable tear film produces dips and losses in visual field testing that mimic glaucoma progression. Distinguishing true nerve damage from tear-film artefact requires a clinician who is looking for both.

Quality of life

Glaucoma itself does not hurt and often produces no symptoms until late. But the treatment — the drops — can make patients miserable. Chronic ocular surface pain, light sensitivity, and fluctuating vision are quality-of-life burdens that patients often accept as inevitable. They are not inevitable.


How Do We Assess This in the Clinic?

A comprehensive evaluation for a glaucoma patient with ocular surface complaints includes:

  • Tear film assessment: Tear breakup time (TBUT) measures how quickly your tear film breaks apart after a blink. In dry eye, this is shortened.
  • Ocular surface staining: Fluorescein and lissamine green dyes reveal damaged cells on the cornea and conjunctiva.
  • Meibomian gland evaluation: Most dry eye in glaucoma patients is evaporative, caused by dysfunction of the oil-producing meibomian glands at the lid margins.
  • Symptom questionnaires: Validated tools like OSDI (Ocular Surface Disease Index) capture the patient experience beyond what the slit lamp shows.
  • Review of the current drop regimen: How many drops, which preservatives, how many times daily.

What Are the Management Options?

Switching to preservative-free formulations

This is often the single most impactful intervention. Preservative-free glaucoma drops deliver the same intraocular pressure-lowering effect without the chronic ocular surface toxicity. Multiple classes of glaucoma medication are now available in preservative-free formats: prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors, and fixed-dose combinations.

The transition requires some planning — not all formulations are available in preservative-free versions in every market, and cost is a factor — but for patients with documented ocular surface disease, this is a clinically justified switch that most guidelines now support.

Fixed-dose combination drops

Instead of using two bottles separately (each with its own preservative load), a fixed-dose combination delivers two active ingredients in one drop. This halves the number of preservative exposures per day. For patients who genuinely need two active agents, this is a practical step even before moving to preservative-free options.

Treating the dry eye directly

Ocular surface disease responds to targeted treatment. The approach depends on the type and severity:

  • Artificial tears: Lubricating drops, preferably preservative-free, used consistently throughout the day. These dilute residual BAK, stabilise the tear film, and reduce surface friction.
  • Warm compresses and lid hygiene: For meibomian gland dysfunction, daily warm compress application followed by gentle lid massage improves the quality of the oily tear layer.
  • Omega-3 supplementation: Good evidence supports dietary omega-3 fatty acids for meibomian gland function and tear quality.
  • Anti-inflammatory therapy: Topical cyclosporine (Restasis, Ikervis) or lifitegrast addresses the inflammatory cycle that perpetuates chronic dry eye. In patients with significant ocular surface inflammation, this can be transformative.
  • Punctal plugs: Small silicone plugs inserted into the tear drainage points slow the drainage of natural tears, keeping the eye surface better hydrated.

Laser and surgical IOP control

For some patients, reducing or eliminating the need for topical drops altogether is the right goal. Selective laser trabeculoplasty (SLT) can lower IOP without any drops. For more advanced glaucoma, surgical options including minimally invasive glaucoma surgery (MIGS) and trabeculectomy may reduce drop burden significantly. When a patient’s ocular surface is severely compromised by long-term drop use, a surgical discussion is worth having.


A Note on Sequence and Timing

When a patient presents with both conditions, the sequence of assessment matters. Dry eye can artificially distort IOP readings and OCT quality. I prefer to stabilise the ocular surface first — or at least treat both simultaneously — so that subsequent glaucoma monitoring data is reliable. A visual field test performed through an unstable tear film is not a trustworthy test.


What Should You Tell Your Doctor?

If you are being treated for glaucoma and your eyes feel uncomfortable, please say so explicitly. Many patients assume irritation is part of the package and do not raise it. Your doctor needs to know:

  • Which symptoms bother you most (burning, grittiness, blurred vision, light sensitivity)
  • Whether symptoms are worse at certain times of day or after drop instillation
  • Whether you have ever reduced or skipped your drops because of discomfort
  • Whether you use a screen for extended hours daily

This information changes the clinical approach. It does not make you a difficult patient — it makes your care more precise.


Frequently Asked Questions

Can glaucoma drops cause dry eye?

Yes. Most glaucoma drops contain benzalkonium chloride, a preservative that damages the ocular surface over time. Long-term exposure causes inflammation, goblet cell loss, and dry eye disease. Switching to preservative-free formulations often brings significant relief.

Do I have to choose between treating my glaucoma and treating my dry eye?

No. Both conditions can and should be managed simultaneously. In many cases, treating dry eye actively improves the tolerability of glaucoma drops and supports adherence to treatment, which protects the optic nerve.

Are preservative-free glaucoma drops as effective as regular drops?

Yes. The active ingredient is the same. The preservative is only there to keep the bottle sterile between uses. Preservative-free formulations use single-dose units instead, delivering the same intraocular pressure-lowering effect without the surface toxicity.

Can dry eye affect my glaucoma test results?

Yes. An unstable tear film causes variable IOP readings and artefacts in visual field and OCT testing. This is one reason a thorough ocular surface assessment is part of comprehensive glaucoma care.

I use three different glaucoma drops. Is that a problem for my eyes?

Three separate bottles often means three doses of BAK per application. This is a significant preservative load. A conversation about fixed-dose combinations or preservative-free alternatives is worth having with your glaucoma specialist.

Is laser treatment an option if my eyes cannot tolerate drops?

Yes. Selective laser trabeculoplasty (SLT) can lower IOP and reduce dependence on drops. For patients whose ocular surface disease is severe and driven by drop toxicity, reducing the drop burden through laser or surgery is a clinically sound strategy.


Internal Linking Architecture Statement

This page is part of the Glaucoma Hub hub. Read about our full approach to glaucoma diagnosis, monitoring, and treatment. Please also read our Dry Eye Hub. Here’s another heartening patient story: Tired of glaucoma eyedrops.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Read More

Basics of Dry Eye, Dry Eye Second Opinion, Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often? Menopause and Dry Eye

Dry Eyes: Natural Remedies, Dry Eyes: Tips to Soothe Sore Eyes

Why Dry Eye Is Worse in Air Conditioning and on Flights

Screen Fatigue, Why Vision Becomes Blurred After Reading or Screen Use,

Why Your Eyes Water Constantly, Omega-3 and Dry Eye, Why Are Your Dry Eye Drops Not Working

Glaucoma Eye Drops: The Complete Guide, Laser or Eye Drops for Glaucoma

Managing Glaucoma Eye Drop Side Effects, Which Is the Best Eyedrop for Glaucoma?

Why Do I Need So Many Glaucoma Eye Drops?

Why Do I Need Glaucoma Treatment If My Vision Seems Normal?

Glaucoma often causes permanent optic nerve damage long before noticeable vision loss develops. Treatment is designed to protect your future vision by slowing or preventing progression before symptoms appear, Dr Shibal Bhartiya explains.

Your vision feels fine. No pain, no blur, no obvious change. So why is your doctor urging treatment? This is the most common question glaucoma patients ask, and it deserves a direct, honest answer,

Glaucoma destroys your optic nerve silently. By the time you notice something is wrong, you have already lost nerve fibres that will never return. Treatment does not restore what is gone. It protects what remains.


The Vision You Have Now Is Not the Vision You Started With

Glaucoma removes peripheral vision first. Your central vision stays sharp until the disease is advanced. Your brain also compensates, filling in blind areas so skilfully that you do not notice them. You may have lost 30 to 40 percent of your optic nerve fibres before any symptom appears.

This is why “I can see fine” is not a safe reassurance in glaucoma. It reflects the vision that has survived, not the vision that has been lost.


Why Glaucoma Treatment Feels Unnecessary (And Why That Feeling Is Dangerous)

Glaucoma drops do not improve your vision. They do not reduce pain because glaucoma causes none. They do not change how things look today. Their only job is to lower the pressure inside your eye and slow the damage to your optic nerve.

When a treatment produces no felt benefit, stopping it feels harmless. This is the central psychological trap in glaucoma care. Patients who feel well skip doses, delay refills, or discontinue treatment altogether. The nerve continues to deteriorate. By the time symptoms appear, the loss is severe and permanent.

The absence of symptoms is not evidence that you are safe. It is evidence that the disease has not yet crossed your threshold of awareness.


What the Research Actually Shows

Studies consistently show that controlling eye pressure reduces the risk of glaucoma progression. The Ocular Hypertension Treatment Study showed that lowering pressure by 20 percent reduced conversion to glaucoma by more than half. The Early Manifest Glaucoma Trial showed that each mmHg reduction in pressure produced a measurable reduction in progression risk.

You are not treating a feeling. You are treating a measurable biological risk that happens to produce no warning before it causes irreversible harm.


“But My Pressures Are Controlled Now — Do I Still Need Drops?”

Yes. Controlled pressure means the treatment is working. Stopping treatment removes the protection. Pressure typically rises again within days to weeks after discontinuation.

Some patients assume that normal pressure readings mean the problem is resolved. Glaucoma is a chronic condition. Controlled pressure is a maintained state, not a cured one.


Normal-Tension Glaucoma: When Pressure Is Not Even the Full Story

A significant group of patients develop glaucoma with eye pressures in the statistically normal range. Their optic nerves are still vulnerable, often due to poor blood flow, structural susceptibility, or other factors. For these patients, the question “but my pressure is fine” does not mean treatment is unnecessary. It means the target pressure needs to be set lower, and other risk factors need attention.

This is one reason that glaucoma management requires individual assessment, not a one-size guideline.


FAQ

If I have no symptoms, does that mean my glaucoma is mild?

Not necessarily. Glaucoma can cause significant optic nerve damage before any symptom appears. The severity of glaucoma is assessed through structural tests like OCT and functional tests like visual fields, not through how your vision feels day to day.

What happens if I skip my glaucoma drops for a few days?

Eye pressure can rise within 24 to 48 hours of stopping treatment. Over time, this pressure exposure adds to cumulative nerve damage. Occasional missed doses are less harmful than long gaps, but no dose-skipping is risk-free in active glaucoma.

Can I know if my glaucoma is getting worse?

Progression is detected through serial OCT scans and visual field testing, not through symptoms. This is why regular follow-up is essential even when your vision feels unchanged.

My doctor wants to change my drops. Should I get a second opinion first?

A second opinion is always appropriate in glaucoma, especially if you are uncertain about treatment changes, surgical recommendations, or whether your current regimen is adequate. Glaucoma causes irreversible loss, so the cost of a wrong decision is permanent.

Are there people who do not need treatment despite a glaucoma diagnosis?

In very early suspected glaucoma or ocular hypertension with low risk factors, observation may be appropriate rather than immediate treatment. This is a clinical judgement based on your individual risk profile, your optic nerve appearance, and your visual field results. It requires an experienced glaucoma specialist to make that call correctly.


What You Should Expect From Your Glaucoma Care

A good glaucoma consultation does more than prescribe drops. It establishes your target pressure based on your stage of disease, your age, and your life expectancy. Also, it identifies your progression rate through serial testing. It reviews whether your current treatment is achieving that target. And it explains, clearly, what is at stake if treatment is inconsistent.

If you have left a consultation without understanding why your specific pressure target was chosen, that is worth asking about. If you are uncertain whether your glaucoma is stable or progressing, that is worth investigating through formal visual field and OCT trend analysis.


A Note on Seeking a Second Opinion

Glaucoma decisions carry permanent consequences. Second opinions are not a sign of distrust toward your current doctor. They are a rational response to a disease where the cost of under-treatment is irreversible. An independent review of your scans and pressure history can confirm that you are on the right path, or catch something that has been missed.


This page is part of the Glaucoma Hub hub. Read about our full approach to glaucoma care. Please also read our Second Opinion Hub. Please also read Glaucoma Diagnosis, first 90 days; and Glaucoma Treatment

Here’s another heartening patient story: Tired of drops


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Glaucoma Diagnosis: First 90 Days

A glaucoma diagnosis can feel overwhelming, but the first 90 days are crucial for understanding your condition, starting treatment, and establishing a plan to protect your vision long term. Early follow-up, regular eye pressure monitoring, and clear communication with your glaucoma specialist can make a significant difference in preserving sight.

Your First 90 Days With Glaucoma: A Step-by-Step Action Plan

Many patients ask me: I have been diagnosed with glaucoma. What do I do now. Here is what I tell them: A glaucoma diagnosis does not mean you are going blind. It means you now have information most people get too late. The next 90 days are the most important window — not because the disease moves fast, but because the habits you build now protect your vision for the next 30 years.

This guide, written by Dr Shibal Bhartiya, tells you exactly what to do, in order.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


Day 1–7 of Glaucoma Diagnosis: Get the Basics Right

Learn to put in your eye drops correctly

This is the single most important skill you will learn. Studies show that over 60% of patients use eye drops incorrectly — and incorrect technique means the drop misses the eye, or drains immediately into the tear duct and does nothing.

Do this:

Wash your hands. Tilt your head back. Pull your lower eyelid gently down to form a pocket. Hold the bottle above the eye without touching it. Squeeze one drop into the pocket — not onto the eyeball directly. Close your eye gently. Press the inner corner of your eye (near the nose) firmly with one finger for 60 seconds. This blocks the tear duct and keeps the drug in the eye where it belongs. Do not blink vigorously. Do not wipe.

If you use more than one drop type, wait five minutes between them. The first drop dilutes and flushes out the second if you use them together.

Ask your doctor or optometrist to watch you do it once. Ask for a correction if your technique needs adjustment.

Here’s a video demostration:

Set your alarms — and take them seriously

Glaucoma drops work only when taken on time, every day, for life. A single missed day matters less than a pattern of casual delays.

Most drops are once daily, ideally at night. Set a recurring alarm on your phone with a label — “Left eye drop, right eye drop, press corner.” Place the bottle next to your toothbrush. The habit links to the existing habit.

If you use drops twice daily, set both alarms. Never rely on memory alone.

File your papers before they disappear

You walked out of the clinic with reports. Photograph or scan every one of them today — the visual field test, the OCT nerve scan, the IOP readings, the prescription. Put them in a dedicated folder on your phone or email them to yourself with the subject line “Glaucoma Records — [your name].”

You will need these at your next visit, at any second opinion, and if you travel and need emergency eye care. Doctors cannot make good decisions without your baseline.


Week 2–4 of Glaucoma Diagnosis: Build the Follow-Up Structure

Your 30-day appointment is not optional

Glaucoma drops take four to six weeks to show their full pressure-lowering effect. Your doctor needs to see you at 30 days to measure whether the drop is working — and to catch side effects early. Do not skip this.

At this visit, your doctor will check:

  • Your intraocular pressure (IOP) against your baseline
  • Whether the drop is causing redness, allergy, or discomfort
  • Whether you need a dose adjustment or a switch to a different medication

Set a calendar reminder for this appointment the day you are diagnosed. If the appointment was not scheduled, call the clinic and schedule it yourself before the week is over.

Know what side effects to watch for

Most glaucoma drops are well-tolerated. But some cause changes you should know about.

Prostaglandin analogues (bimatoprost, travoprost, latanoprost) can darken the iris over time in some patients, and may cause eyelash growth or mild redness. These are cosmetic and not dangerous — but tell your doctor.

Beta-blockers (timolol) can slow your heart rate and cause breathlessness in patients with asthma or heart disease. If you feel unusually short of breath or very tired after starting drops, contact your doctor the same day.

Alpha agonists (brimonidine) sometimes cause an allergic reaction with marked redness and discharge, usually within weeks of starting. Stop the drop and call your doctor if this happens.

None of these mean you must stop treatment. They mean the treatment may need adjustment.


Month 1–2 of Glaucoma Diagnosis: Tell Your Family

Your siblings and children need an eye check — now

Glaucoma has a strong genetic component. First-degree relatives of a glaucoma patient have a four to nine times higher risk of developing the disease. Most of them will have no symptoms at all until damage is advanced.

Tell your siblings and adult children this week. Ask them to see an ophthalmologist for a baseline pressure check, optic nerve assessment, and field test. This is not alarmist. It is the most useful thing your diagnosis can do for your family.


Month 1–3: Address the Controllable Risk Factors

Stop smoking — this one is not negotiable

Smoking constricts blood vessels and reduces blood flow to the optic nerve. It worsens the vascular risk that many glaucoma patients already carry. The damage from smoking adds to the damage from pressure — and your nerve cannot absorb both.

If you smoke, speak to your doctor about cessation support. This is as important as the drops.

Get your metabolic parameters checked

High blood pressure, diabetes, thyroid disease, and sleep apnoea all affect glaucoma progression through vascular and metabolic pathways. If these are uncontrolled, your optic nerve faces risk from two directions simultaneously.

Ask your physician to check your blood pressure, fasting glucose, HbA1c, and thyroid function if these have not been done recently. If you snore heavily or feel exhausted in the mornings, mention it — untreated sleep apnoea is a recognised glaucoma risk factor that is almost always missed.

Exercise — the right kind

Moderate aerobic exercise (brisk walking 30 minutes, five days a week) lowers intraocular pressure by a clinically meaningful amount in most patients. Avoid high-resistance head-down exercises like heavy weightlifting or inverted yoga poses — these transiently spike IOP.


Month 2–3: Ask About Laser Treatment

SLT — Selective Laser Trabeculoplasty

If your glaucoma is open-angle type, your doctor may recommend SLT as a first-line treatment or as a supplement to drops. SLT uses a laser to improve fluid drainage from the eye. It is done in the clinic in five to ten minutes, is painless, and works in approximately 75 to 80% of patients.

The effect lasts three to five years and can be repeated. SLT does not burn tissue — it sends a gentle energy pulse that stimulates the drainage cells to work better.

Ask your doctor at the 30-day or 90-day visit: “Am I a candidate for SLT?”

LPI — Laser Peripheral Iridotomy

If your glaucoma is narrow-angle or angle-closure type, LPI is a preventive procedure that creates a small opening in the iris to prevent a sudden pressure spike (acute angle-closure attack). LPI is typically recommended before an attack happens — it takes three to four minutes per eye and prevents one of the most painful ophthalmic emergencies.

If your doctor mentioned narrow angles at any point, ask specifically whether you need LPI. Do not wait.


Throughout: Keep Your Perspective

Do not search the internet at 2am

Glaucoma outcomes in treated patients are overwhelmingly good. The disease moves slowly in the vast majority of cases. Patients who take their drops, attend follow-ups, and manage their risk factors maintain useful vision for life in most cases.

The stories of severe vision loss you will find online mostly involve patients who were never diagnosed, or who stopped treatment. You are neither.

Reach out if you need support

A new diagnosis changes how you think about your body. Some patients find this unsettling, and that is entirely normal. Several Indian and international glaucoma patient forums, and online communities run by ophthalmologists offer peer support from people at every stage of the same journey.

You do not have to figure this out alone.


Your 90-Day Checklist

  • Eye drop technique confirmed by a doctor or technician
  • Alarm set — every day, same time
  • All reports photographed and filed digitally
  • 30-day follow-up appointment booked
  • Side effects list saved on your phone
  • Siblings and adult children informed and booked for screening
  • Smoking cessation initiated if applicable
  • Blood pressure, glucose, HbA1c, thyroid checked
  • SLT or LPI discussion had with your doctor
  • One support resource bookmarked

Frequently Asked Questions

Do I have to take eye drops for life?

In most cases, yes. Glaucoma is a chronic condition and eye drops control pressure — they do not cure the disease. Stopping drops allows pressure to rise again and damage to resume. Some patients reduce or stop drops after successful laser treatment (SLT), but this is a decision made with your doctor based on your pressure readings, not independently.

What if I forget a drop one day?

Take it as soon as you remember, unless it is almost time for the next dose. Do not double up. One missed dose will not cause a crisis. A habit of casual misses will. Reset the alarm and continue.

Can I drive after putting in my eye drops?

Most glaucoma drops do not affect vision significantly. Some patients notice mild blurring for a few minutes immediately after instillation — wait for this to clear before driving. If your doctor has dilated your pupils at a clinic visit, do not drive until dilation wears off, typically three to four hours.

My pressure was normal at diagnosis. Do I still have glaucoma?

Yes — this is called normal-tension glaucoma (NTG). Roughly 30 to 40% of glaucoma patients in India have pressures within the statistical normal range. The diagnosis is made on optic nerve appearance and visual field changes, not pressure alone. NTG is treated the same way — the target is to lower pressure further from your individual baseline.

Is glaucoma hereditary? Do I need to tell my family?

Yes, and yes. First-degree relatives — parents, siblings, children — have a four to nine times higher risk. Most will have no symptoms. Tell them this week and ask them to see an ophthalmologist for a baseline check that includes pressure, nerve assessment, and a visual field test.

Will I go blind?

Treated glaucoma in a compliant patient who attends follow-up carries a very low risk of blindness. The risk is real only when the disease is undiagnosed, undertreated, or ignored. You have been diagnosed. That is the most important step already taken.

What is SLT and should I ask about it?

Selective Laser Trabeculoplasty (SLT) is a five-minute clinic procedure that improves fluid drainage from the eye. It works in approximately 75 to 80% of open-angle glaucoma patients and can reduce or eliminate the need for drops for three to five years. Ask your doctor at the 30-day visit whether you are a candidate.

Can I exercise with glaucoma?

Yes — moderate aerobic exercise is actively beneficial and lowers IOP. Brisk walking, cycling, and swimming are all good. Avoid heavy resistance training with breath-holding (Valsalva manoeuvre) and inverted positions, both of which spike pressure transiently. If exercise is a regular part of your routine, tell your doctor so they can factor it into your pressure readings.

My drops are making my eyes red. Should I stop?

Do not stop without speaking to your doctor first. Redness is common with several drop classes and is often manageable — a preservative-free formulation or a switch in medication resolves it in most cases. Stopping drops independently allows pressure to rise. Call the clinic and describe the symptom.

How often will I need follow-up forever?

Once stable on treatment, most patients are reviewed every three to six months. This includes a pressure check and, once yearly or more often if needed, a repeat visual field test and OCT nerve scan to confirm the disease is not progressing. Glaucoma never becomes self-managing — the follow-up rhythm continues for life, but it is not onerous once the initial titration phase is complete.


This page is part of the Glaucoma Hub hub. Read about our full approach to glaucoma care and monitoring. Please also read our guide to Understanding Your Visual Field Test. You may want to read a patient’s experience with glaucoma eye drops, and of one with SLT.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Travelling To India for Eye Care

Travelling to India for eye treatment? Travel for medical care is not simply about finding treatment. It is about finding the right diagnosis, understanding your options, and making important decisions with confidence. Dr Shibal Bhartiya provides specialist eye care for international patients seeking expert evaluation, second opinions, advanced diagnostics, and long-term management of complex eye conditions.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

Expert Eye Care in India for Patients Seeking Clarity, Confidence, and Specialist Opinion

GlaucomaNeuro-OphthalmologyDry Eye & Ocular Surface DiseaseComplex Eye Care

Patients travel from the UK, USA, UAE, Singapore, Bangladesh, Nepal, East Africa, and across South Asia for consultations focused on careful assessment, evidence-based recommendations, and clear communication.

25+ Years Experience | 200+ Publications | 28 Textbooks | 1,500+ Five-Star Reviews | International Patients from 20+ Countries | 40000+ patients


Why International Patients Choose Dr Shibal Bhartiya

A Specialist Perspective for Complex Problems

Many patients seeking international consultations are not looking for another routine eye examination.

They are seeking answers to questions such as:

  • Am I actually progressing?
  • Do I really need surgery?
  • Why do my symptoms not match my test results?
  • Has something important been missed?
  • Why am I still struggling despite treatment?
  • Should I seek a second opinion before making a major decision?

Our consultations are designed to answer these questions through detailed evaluation, advanced diagnostics, and careful clinical interpretation.


Areas of Special Expertise

Glaucoma

Glaucoma is often diagnosed late because patients may continue seeing well while irreversible damage accumulates silently.

Dr Bhartiya’s glaucoma practice focuses on:

  • Early glaucoma diagnosis
  • Glaucoma suspects and risk assessment
  • Progression analysis
  • Normal tension glaucoma
  • Complex glaucoma management
  • Surgical decision-making
  • Second opinions before surgery
  • Long-term vision preservation strategies

Many international patients seek consultation after receiving conflicting advice or when they are uncertain whether treatment escalation is truly necessary.

You can read more about glaucoma here


Neuro-Ophthalmology

Neuro-ophthalmology bridges the gap between ophthalmology and neurology.

Common reasons for referral include:

  • Optic nerve disorders
  • Unexplained visual loss
  • Visual field abnormalities
  • Pituitary-related visual problems
  • Double vision
  • Intracranial hypertension
  • Neurological causes of visual symptoms
  • Complex diagnostic uncertainty

Patients are often referred after multiple consultations when symptoms, scans, and examinations do not fit together neatly.

You can read more about neuro-ophthalmology care here


Dry Eye & Ocular Surface Disease

Many patients with ocular surface disease have been treated repeatedly without understanding the underlying drivers of their symptoms.

Areas of focus include:

  • Chronic dry eye disease
  • Meibomian gland dysfunction
  • Ocular surface inflammation
  • Computer-related eye strain
  • Autoimmune ocular surface disease
  • Refractory dry eye
  • Ocular GVHD
  • Complex ocular discomfort syndromes

The goal is not simply prescribing more drops, but understanding why symptoms persist.

You can read more about ocular surface diseases including dry eye, and allergies, here


Comprehensive Ophthalmology & Diagnostic Second Opinions

Not every patient arrives with a diagnosis.

Many simply know that something is wrong.

We frequently evaluate patients seeking answers regarding:

  • Unexplained visual symptoms
  • Diagnostic uncertainty
  • Cataract and glaucoma overlap
  • Complex treatment decisions
  • Risk assessment before intervention
  • Long-term monitoring plans

Explore Our Specialist Eye Care Services

International patients often arrive with a diagnosis, a recommendation, or simply a concern that something is being missed.

While glaucoma, neuro-ophthalmology, and ocular surface disease are areas of particular expertise, every patient journey is different. Explore our specialist services below to better understand your condition and the options available.

Glaucoma Care

Glaucoma can cause permanent vision loss before symptoms become obvious. Learn about glaucoma diagnosis, risk assessment, progression monitoring, treatment options, and specialist second opinions.

Explore Glaucoma Care →


Neuro-Ophthalmology

Visual symptoms are not always caused by the eye itself. Neuro-ophthalmology evaluates disorders affecting the optic nerve, visual pathways, eye movements, and the connection between the eye and brain.

Explore Neuro-Ophthalmology →


Dry Eye & Ocular Surface Disease

Persistent irritation, burning, watering, fluctuating vision, and discomfort often require a deeper evaluation than routine eye examinations provide. Learn more about dry eye disease, meibomian gland dysfunction, ocular GVHD, and ocular surface disorders.

Explore Dry Eye & Ocular Surface Disease →


Second Opinions

Many patients seek reassurance before surgery, treatment escalation, or major decisions. A specialist second opinion can provide clarity, confirm a diagnosis, or identify alternative approaches.

Explore Second Opinions →


Advanced Diagnostic Testing

Accurate diagnosis depends on more than a single test result. Learn how OCT imaging, visual field analysis, optic nerve evaluation, and ocular surface assessment contribute to clinical decision-making.

Explore Advanced Diagnostics →


Comprehensive Eye Care

Not every patient arrives with a diagnosis. Some simply know that their vision has changed or that something does not feel right. Explore common eye conditions, symptoms, and specialist evaluation pathways.

Explore Comprehensive Eye Care →

Whether you are seeking a second opinion, treatment recommendations, or answers to a complex diagnostic question, our goal is to help you understand your condition clearly and make confident decisions about your eye health.

Popular Searches: glaucoma specialist India, neuro-ophthalmologist India, dry eye specialist India, glaucoma second opinion India, ocular surface disease specialist India, international eye specialist India, advanced eye care India, ophthalmologist for international patients.


International Patient Journey

Step 1: Send Your Records

Before travelling, patients may share:

  • Previous consultation notes
  • OCT scans
  • Visual field reports
  • MRI or CT reports
  • Surgical recommendations
  • Current medication lists

This allows preliminary review and helps ensure efficient use of consultation time.


Step 2: Pre-Visit Review

Records are reviewed before your appointment whenever possible.

This means consultations begin with context rather than starting from zero.


Step 3: Specialist Evaluation

Consultations may include:

  • Comprehensive examination
  • Advanced imaging
  • Functional testing
  • Risk assessment
  • Discussion of treatment options
  • Clarification of previous findings

Most investigations can be completed in a single visit.


Step 4: Written Clinical Opinion

Patients receive:

  • Detailed findings
  • Interpretation of investigations
  • Diagnosis (where possible)
  • Treatment recommendations
  • Follow-up strategy

Reports can be shared with treating doctors in the patient’s home country to support continuity of care.


Step 5: Ongoing Follow-Up

Many eye conditions require continuity rather than isolated intervention.

Where appropriate, follow-up planning may include:

  • Remote review of reports
  • Communication with local specialists
  • Monitoring recommendations
  • Long-term management planning

Why Patients Travel to India

India offers access to:

  • Advanced ophthalmic diagnostics
  • Internationally recognised specialists
  • Minimal waiting times
  • Comprehensive investigations in one location
  • Cost-effective care compared with many Western healthcare systems

Many patients are able to complete evaluation and decision-making within a short visit.


About Dr Shibal Bhartiya

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist with over 25 years of clinical experience. Her work combines clinical care, research, education, and international collaboration.

Highlights include:

  • Fellowship-Trained Glaucoma Specialist
  • Mayo Clinic Research Collaborator
  • 200+ Scientific Publications
  • 90+ PubMed-Indexed Papers
  • 28 Edited Textbooks
  • Editor-in-Chief, CLEVER
  • Executive Editor, Journal of Current Glaucoma Practice
  • International Speaker and Research Collaborator

Languages Spoken

To make complex medical discussions easier for international patients, consultations may be conducted with an interpreter, or facilitator if required. However, Dr Shibal Bhartiya speaks several languages:

  • English
  • Hindi
  • Urdu
  • French
  • Bangla (conversational)
  • Arabic (basic conversational)
  • Persian / Farsi (basic conversational)

Medical records and formal clinical documentation are provided in English, and may be provided in Hindi, French or Urdu on request .


Frequently Asked Questions

Can I send my reports before travelling?

Yes. Sharing reports beforehand helps determine what additional testing may be needed and allows more focused consultations.

Can I obtain a second opinion without surgery?

Absolutely. A large proportion of international patients seek clarity and confirmation before making treatment decisions.

How long should I stay in India?

Most second-opinion evaluations can be completed within 2–3 days. Surgical patients may require longer depending on the procedure.

Will my doctor at home receive a report?

Yes. With your permission, a detailed written opinion can be shared with your treating physician.

Do you assist with medical visa documentation?

Supporting medical documentation can be provided where required.


Send Your Reports Before You Travel

If you are considering travelling to India for glaucoma, neuro-ophthalmology, dry eye treatment, or a specialist second opinion, the process can begin before you leave home.

Send your reports, scans, or questions for review.

Dr Shibal Bhartiya
Glaucoma • Neuro-Ophthalmology • Advanced Eye Care • Second Opinion

🌐 www.drshibalbhartiya.com
📞 +91 88826 38735


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Can Ocular GVHD Cause Dry Eyes?

Ocular GVHD is an eye condition that can develop after bone marrow or stem cell transplant, causing dry eyes, irritation, and fluctuating vision even after the main illness stabilises. Long-term follow-up helps protect the ocular surface, support daily function, and prevent slow, quiet damage from becoming permanent.

Here’s the story of a young girl’s grit and determination, as she battle GVHD. She is now a DOCTOR herself!!


She Came Back Every Holiday

A clinical story about ocular GVHD, dry eyes, and what it means to stay

Some patients stay in your memory because the diagnosis was rare.

Others stay because you realise, years later, that you were not just treating a condition. You were quietly watching somebody become who they were going to be.

I first met her when she was fifteen or sixteen. She had already been through more than most adults carry in a lifetime. She had undergone a bone marrow transplant. And afterwards, she developed ocular graft-versus-host disease — ocular GVHD.

Families who arrive after transplantation carry a particular kind of relief. The worst has happened. Treatment happened. Something enormous has been crossed. But uncertainty travels with them, because the body does not always stop at the finish line of the illness that was treated.

Then the eyes become part of the story.


What Ocular GVHD Feels Like From the Inside

Most people imagine ocular GVHD as something visibly dramatic. Sometimes it is. But for many patients, it arrives quietly.

Dryness that feels like something is always wrong, even on a good day. Burning that begins before the rest of the body feels tired. Vision that stays technically normal but no longer feels effortless.

Reading that becomes work. Studying that becomes slower. Screen time that was once easy and now costs something.

She was fifteen. She was trying to get back to school. She was trying to become a teenager again, the way teenagers are supposed to be — carelessly occupied with the future. And every day, her eyes made that harder.


Managing Ocular GVHD: What Actually Helps

Over the months that followed, we worked through treatment together. We managed her ocular surface carefully. We adjusted care as her symptoms changed. The active ocular GVHD gradually settled. Her vision got better. The comfort improved. Her reading improved. She got back to school.

But as so often happens with ocular GVHD, the story did not simply end when the acute phase resolved. She continued to have dry eyes. Frequent inflammation, sudden flare ups. Good months and difficult ones. The kind of low-grade, persistent vulnerability that does not make headlines but shapes ordinary days.

Steroids, in varying strengths, and frequency; lubricating eyedrops. Her BMT specialist and I, spoke about her thrice a day on some days, and some times, not even once a month.

She lived in Lucknow. Not nearby. And yet she kept coming back. Every few months. Then every holiday. Keeping in touch over the phone. Sometimes, just to talk. And we kept titrating her treatment to her symptoms, and to the disease activity.

Not because something dramatic was happening. Not because her vision was deteriorating. She came because follow-up had quietly become part of how she looked after herself. She understood, at sixteen, what many adults take years to learn: that a condition managed well is a condition you stop noticing.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google


What Patients Actually Remember

Doctors tend to think patients remember the treatment.

Patients usually remember something else. They remember whether someone recognised them the next time they walked in. They remember not having to explain everything from the beginning. They remember the quality of continuity more than the quality of any single intervention.

She sat her Class 12 examinations. Then she prepared for medical entrance exams.

One day she came to see me with her parents. Her eyes were stable. Her vision was good. She had come not because she needed treatment, but because she had received a medical school offer and wanted advice.

Which college. Which city. Whether to go far from home. We sat and talked. Years earlier we had been discussing tear films and corneal staining and drop regimens. Now we were discussing hostels and futures and what she wanted her life to look like.

She chose South India. She started medical school. Her parents were apprehensive because it was far away. Dr Shibal, she said, you can take care of me long distance, can’t you? I gave her a hug.

Your medical college will have an eye doctor, love. Yes, she said, but they’ll not be you.

And she still comes back. Every six months. Every holiday.

At one visit, she smiled and said something I still think about.

My vision is pristine.

I had to pause with that for a moment.

Because I do not think patients become doctors because someone cured them. I think sometimes they become doctors because someone stayed. Because someone showed them, over years of ordinary appointments, what it looks like to pay close attention to a person who is quietly carrying something.


This Is Not a Story About a Perfect Outcome

Her eyes still need looking after. She still struggles in difficult stretches. And is on medication. She still follows up.

But she built a life. She studied. And left home. She entered medicine. And every time she walks back into my clinic, I am reminded that the most important things in practice do not happen in the moments of diagnosis or surgery or crisis.

They happen in the reviews. The adjustments. The small, ordinary appointments where someone walks in and you already know who they are.

That is where medicine actually changes lives.

Last month, she graduated from medical school.


What Is Ocular GVHD?

Ocular graft-versus-host disease (ocular GVHD) is an eye condition that can develop after bone marrow or stem cell transplant. Donor immune cells may attack the tear glands and ocular surface, causing dryness, inflammation, and changes in visual comfort that persist long after the transplant itself has stabilised.

Symptoms can continue, fluctuate, or remain low-grade for years. Because of this, patients often benefit from long-term ophthalmic follow-up even when their systemic illness is well controlled and their measured vision remains good.

Symptoms of Ocular GVHD include:

Dry eyes, burning, irritation, fluctuating vision, redness, light sensitivity, watering, eye fatigue, difficulty reading or using screens for extended periods, and persistent ocular surface sensitivity that worsens with study, work, or environmental change.


How is Ocular GVHD classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.

Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.


When Should You See an Eye Specialist?

If you or your child has undergone a bone marrow or stem cell transplant and you notice persistent dryness, redness, fluctuating vision, burning, or discomfort — do not assume this is simply part of recovery.

The ocular surface can remain affected even after systemic disease feels far behind you. Early evaluation may preserve comfort, function, and long-term visual quality.

Known for her structured approach to vision risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.


This page is part of the Dry Eye Disease hub . Read about our full approach to GVHD, Dry Eyes and children’s eye care. Please also read Pediatric Eye Care hub

Here’s another heartening patient story: A young boy and his love for trucks


FAQs:

What is ocular GVHD?

Ocular GVHD is a complication that can develop after bone marrow or stem cell transplant. Donor immune cells affect the tear glands and eye surface, causing dryness, inflammation, and visual discomfort that may persist long after the main transplant illness stabilises.

What are the common symptoms?

Dry eyes, burning, fluctuating vision, redness, irritation, light sensitivity, watering, difficulty reading, and visual fatigue that worsens with screens or study.

Can ocular GVHD improve over time?

Yes. Many patients improve significantly, particularly with consistent treatment and close follow-up. Some continue to experience low-grade dryness or surface sensitivity for years. This does not mean the condition is untreatable — it means it requires sustained attention rather than a single course of treatment.

Can patients with ocular GVHD study, work, and live normally?

Many can, particularly when symptoms are identified early and managed consistently. The goal of treatment is not only to protect vision but to restore the quality of everyday life — reading, screens, study, and all the things that ordinary days are made of.

Why is long-term follow-up important?

Symptoms and underlying ocular surface health do not always change in parallel. A patient may feel stable and still have ongoing surface changes that benefit from monitoring. Regular review allows treatment to be adjusted before problems compound.

Does ocular GVHD affect children and young people differently?

The condition affects children and adolescents at a time when study load, screen use, and daily reading demands are high. Symptoms that an adult might manage around can significantly affect a young person’s academic performance and sense of normalcy. Recognising this early changes what the follow-up plan should look like.

About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google